An active phase I study was designed to evaluate the safety and tolerance of tremelimumab, anti‐CTLA‐4 antibody and durvalumab in various advanced solid tumours including cervical cancer (NCT01975831). The gene discussed is CTLA4; the disease is cervical carcinoma.